-
Something wrong with this record ?
The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review
J. Prochazkova, L. Slavik, J. Ulehlova, M. Prochazka
Language English Country Czech Republic
Document type Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review
Grant support
NT14394
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
25559093
DOI
10.5507/bp.2014.061
Knihovny.cz E-resources
- MeSH
- Blood Coagulation physiology MeSH
- Humans MeSH
- Pre-Eclampsia blood etiology MeSH
- Randomized Controlled Trials as Topic MeSH
- Pregnancy MeSH
- Thromboplastin physiology MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
BACKGROUND: Tissue factor (TF) is a key element for normal gestation, especially in the first trimester. TF levels are hence raised in pregnancy, producing an adaptive hypercoagulable state. Potentiated hypercoagulability however, is associated with disorders of pregnancy such as pre-eclampsia but the results of TF and its inhibitor, tissue factor pathway inhibitor (TFPI), measurement, in pre eclampsic women are ambiguous and the data conflicting. This review covers the current knowledge status of the role of TF assessment in pregnancy with a focus on its diagnostic utility. METHODS: A review of the literature using the following key words: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia. RESULTS: The published literature shows raised and unchanged TF levels in various studies of pre-eclampsia along with equally conflicting data for TFPI. The various study designs and methods used in these studies makes valid comparison difficult. Meta analysis of 34 randomized trials showed that low-dose aspirin in early phases of gravidity (starting from the 16th week or earlier) significantly reduces the incidence of preeclampsia. CONCLUSIONS: Overall, the results of the literature search together with knowledge of the structure and biological effects of TF, suggest that measuring the level of plasma TF/TFPI is not ideal for determining the actual levels of TF in the uteroplacental circulation. The current view that endothelial dysfunction is the trigger for preeclampsia, suggests that aspirin may be an effective prophylaxis. Further research will be necessary: measuring the expression of tissue factor on monocytes using flowcytometry and comparing the development of this expression during normal pregnancy and pregnancy complicated by preeclampsia, for example. Another possibility is immunohistochemical determination of the level of TF expression directly in placental tissue.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17006067
- 003
- CZ-PrNML
- 005
- 20181011120407.0
- 007
- ta
- 008
- 170210s2015 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2014.061 $2 doi
- 035 __
- $a (PubMed)25559093
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Procházková, Jana $u Department of Hemato-oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0067433
- 245 14
- $a The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review / $c J. Prochazkova, L. Slavik, J. Ulehlova, M. Prochazka
- 520 9_
- $a BACKGROUND: Tissue factor (TF) is a key element for normal gestation, especially in the first trimester. TF levels are hence raised in pregnancy, producing an adaptive hypercoagulable state. Potentiated hypercoagulability however, is associated with disorders of pregnancy such as pre-eclampsia but the results of TF and its inhibitor, tissue factor pathway inhibitor (TFPI), measurement, in pre eclampsic women are ambiguous and the data conflicting. This review covers the current knowledge status of the role of TF assessment in pregnancy with a focus on its diagnostic utility. METHODS: A review of the literature using the following key words: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia. RESULTS: The published literature shows raised and unchanged TF levels in various studies of pre-eclampsia along with equally conflicting data for TFPI. The various study designs and methods used in these studies makes valid comparison difficult. Meta analysis of 34 randomized trials showed that low-dose aspirin in early phases of gravidity (starting from the 16th week or earlier) significantly reduces the incidence of preeclampsia. CONCLUSIONS: Overall, the results of the literature search together with knowledge of the structure and biological effects of TF, suggest that measuring the level of plasma TF/TFPI is not ideal for determining the actual levels of TF in the uteroplacental circulation. The current view that endothelial dysfunction is the trigger for preeclampsia, suggests that aspirin may be an effective prophylaxis. Further research will be necessary: measuring the expression of tissue factor on monocytes using flowcytometry and comparing the development of this expression during normal pregnancy and pregnancy complicated by preeclampsia, for example. Another possibility is immunohistochemical determination of the level of TF expression directly in placental tissue.
- 650 _2
- $a hemokoagulace $x fyziologie $7 D001777
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a preeklampsie $x krev $x etiologie $7 D011225
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a tkáňový faktor $x fyziologie $7 D013925
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Slavík, Luděk $u Department of Hemato-oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0081908
- 700 1_
- $a Úlehlová, Jana $u Department of Hemato-oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0117725
- 700 1_
- $a Procházka, Martin, $u Department of Obstetrics and Gynecology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc; Department of Midwifery, Faculty of Health Sciences, Palacky University Olomouc $d 1970- $7 xx0019288
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 159, č. 2 (2015), s. 192-196
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170210 $b ABA008
- 991 __
- $a 20181011120858 $b ABA008
- 999 __
- $a ok $b bmc $g 1192592 $s 966714
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 159 $c 2 $d 192-196 $e 20141222 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- GRA __
- $a NT14394 $p MZ0
- LZP __
- $b NLK118 $a Pubmed-20170210